Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease–Driving Inflammation While Promoting Regulatory B Cells
These findings highlight the potential of BTK inhibition as a selective and sustainable immunomodulatory strategy for both B cells and myeloid cells in the context of chronic CNS inflammation. Despite their efficacy, broad-spectrum immunosuppressive therapies often fail to provide targeted immune modulation. By contrast, BTK inhibition promotes regulatory B-cell properties while leaving other B-cell functions intact, providing the basis for its broad use-potentially in combination with established anti-inflammatory agents.
Authors
- Anastasia Geladaris (ORCID: https://orcid.org/0009-0007-4184-6001)
- Marius Ringelstein (ORCID: https://orcid.org/0000-0003-3618-8407)
- Marie Freier (ORCID: https://orcid.org/0009-0009-9829-5217)
- Darius Saberi (ORCID: https://orcid.org/0000-0002-0004-4578)
- Sarah Dybowski (ORCID: https://orcid.org/0000-0001-7762-3255)
- Silke Häusser‐Kinzel (ORCID: https://orcid.org/0000-0003-3226-701X)
- Sebastian Torke (ORCID: https://orcid.org/0000-0002-1029-3623)
- Jacqueline Thode (ORCID: https://orcid.org/0000-0003-0899-1104)
- Martin S. Weber (ORCID: https://orcid.org/0000-0001-8409-0389)
- Stefan Nessler (ORCID: https://orcid.org/0009-0007-8710-5233)
Institutions
- Max Delbrück Center (DE)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Universitätsmedizin Göttingen (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Göttingen (DE)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1212/nxi.0000000000200510
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Biogen
- Teva Pharmaceutical Industries